Improvement of the targeting of radiolabeled and functionalized liposomes with a two-step system using a bispecific monoclonal antibody (anti-CEA × anti-DTPA-In)

Frontiers in Medicine

Volumn 2, Issue NOV, 2015, Pages

  Rauscher, Aurore ^a,b   Frindel, Mathieu ^a,c   Rajerison, Holisoa ^a   Gouard, Sébastien ^a   Maurel, Catherine ^a   Barbet, Jacques ^a,d   Faivre Chauvet, Alain ^a,c   Mougin Degraef, Marie ^a,c  

^a UNIVERSITÉ DE NANTES   (France)

^b Centre Gauducheau Institut de Cancerologie de l'Ouest   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d GIP ARRONAX   (France)

Author keywords

Bispecific antibody; Pegylated liposomes; Pretargeting; Radioimmunotherapy; Solid tumors

Indexed keywords

EID: 85029705489     PISSN: None     EISSN: 2296858X     Source Type: Journal    
DOI: 10.3389/fmed.2015.00083     Document Type: Article

References (27)

1. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol (2002) 20(10):2453-63. doi: 10.1200/JCO.2002.11.076
2. Illidge T, Morschhauser F. Radioimmunotherapy in follicular lymphoma. Best Pract Res Clin Haematol (2011) 24(2):279-93. doi:10.1016/j.beha.2011.03.005
3. Sharkey RM, Goldenberg DM. Cancer radioimmunotherapy. Immunotherapy (2011) 3(3):349-70. doi:10.2217/imt.10.114
4. DeNardo SJ, Denardo GL. Targeted radionuclide therapy for solid tumors: an overview. Int J Radiat Oncol Biol Phys (2006) 66:89-95. doi:10.1016/j.ijrobp.2006.03.066
5. Barbet J, Kraeber-Bodéré F, Vuillez JF, Gautherot E, Rouvier E, Chatal JF. Pretargeting with the affinity enhancement system for radioimmunotherapy. Cancer Biother Radiopharm (1999) 14(3):153-66. doi:10.1089/cbr.1999.14.153
6. Kraeber-Bodéré F, Salaun PY, Ansquer C, Drui D, Mirallié E, Faivre-Chauvet A, et al. Pretargeted radioimmunotherapy (pRAIT) in medullary thyroid cancer (MTC). Tumor Biol (2012) 33(3):601-6. doi:10.1007/s13277-012-0359-6
7. Kraeber-Bodere F, Rousseau C, Bodet-Milin C, Ferrer L, Faivre-Chauvet A, Campion L, et al. Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial. J Nucl Med (2006) 47(2):247-55
8. Goodwin DA, Meares CF. Advances in pretargeting biotechnology. Biotechnol Adv (2001) 19(6):435-50. doi:10.1016/S0734-9750(01)00065-9
9. Phillips WT, Goins B, Bao A. Radioactive liposomes. Nanomed Nanobiotechnol (2009) 1(1):69-83. doi:10.1002/wnan.3
10. Ting G, Chang CH, Wang HE, Lee TW. Nanotargeted radionuclides for cancer nuclear imaging and internal radiotherapy. J Biomed Biotechnol (2010) 2010: 1-17. doi:10.1155/2010/953537
11. Rauscher A, Frindel M, Maurel C, Maillasson M, Le Saëc P, Rajerison H, et al. Influence of pegylation and hapten location at the surface of radiolabelled liposomes on tumour immunotargeting using bispecific antibody. Nucl Med Biol (2014) 41:e66. doi:10.1016/j.nucmedbio.2013.12.012
12. Mougin-Degraef M, Jestin E, Bruel D, Remaud-Le Saëc P, Morandeau L, Faivre-Chauvet A, et al. High-activity radio-iodine labeling of conventional and stealth liposomes. J Liposome Res (2006) 16(1):91-102. doi:10.1080/08982100500528941
13. Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol (1965) 13(1):238-252. doi:10.1016/S0022-2836(65)80093-6
14. Mougin-Degraef M, Bourdeau C, Jestin E, Saï-Maurel C, Bourgeois M, Le Saëc P, et al. Doubly radiolabeled liposomes for pretargeted radioimmunotherapy. Int J Pharm (2007) 344(1-2):110-117. doi:10.1016/j.ijpharm.2007.05.024
15. Oja CD, Semple SC, Chonn A, Cullis PR. Influence of dose on liposomes clearance: critical role of blood proteins. Biochim Biophys Acta (1996) 1281:31-7. doi:10.1016/0005-2736(96)00003-X
16. Wu MS, Robbins JC, Bugianesi RL, Ponpipom MM, Shen TY. Modified in vivo behavior of liposomes containing synthetic glycolipids. Biochim Biophys Acta (1981) 674(1):19-29. doi:10.1016/0304-4165(81)90342-1
17. Torchilin V. Fluorescence microscopy to follow the targeting of liposomes and micelles to cells and their intracellular fate. Adv Drug Deliv Rev (2005) 57(1):95-109. doi:10.1016/j.addr.2004.06.002
18. Düzgünes N, Nir S. Mechanisms and kinetics of liposome-cell interactions. Adv Drug Deliv Rev (1999) 40:3-18. doi:10.1016/S0169-409X(99)00037-X
19. Castelli DD, Terreno E, Cabella C, Chaabane L, Lanzardo S, Tei L, et al. Evidence for in vivo macrophage mediated tumor uptake of paramagnetic/fluorescent liposomes. NMR Biomed (2009) 22(10):1084-92. doi:10.1002/nbm.1416
20. Rangger C, Helbok A, Sosabowski J, Kremser C, Koehler G, Prassl R, et al. Tumor targeting and imaging with dual-peptide conjugated multifunctional liposomal nanoparticles. Int J Nanomedicine (2013) 8:4659-71. doi:10.2147/IJN.S51927
21. Petersen AL, Binderup T, Jølck RI, Rasmussen P, Henriksen JR, Pfeifer AK, et al. Positron emission tomography evaluation of somatostatin receptor targeted 64Cu-TATE-liposomes in a human neuroendocrine carcinoma mouse model. J Control Release (2012) 160(2):254-63. doi:10.1016/j.jconrel.2011.12.038
22. Gabizon A, Horowitz AT, Goren D, Tzemach D, Shmeeda H, Zalipsky S. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. Clin Cancer Res (2003) 9(17):6551-9
23. Maeda H, Bharate GY, Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm (2009) 71(3):409-19. doi:10.1016/j.ejpb.2008.11.010
24. Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res (2006) 13:6732-40
25. Lehtinen J, Raki M, Bergström KA, Uutela P, Lehtinen K, Hiltunen A, et al. Pre-targeting and direct immunotargeting of liposomal drug carriers to ovarian carcinoma. PLoS One (2012) 7(7):e41410. doi:10.1371/journal.pone.0041410
26. Bryan JN, Jia F, Mohsin H, Sivaguru G, Miller WH, Anderson CJ, et al. Comparative uptakes and biodistributions of internalizing vs. non-internalizing copper-64 radioimmunoconjugates in cell and animal models of colon cancer. Nucl Med Biol (2005) 32(8):851-8. doi:10.1016/j.nucmedbio.2005.05.006
27. Boudousq V, Bobyk L, Busson M, Garambois V, Jarlier M, Charalambatou P, et al. Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb. PLoS One (2013) 8(7):e69613. doi:10.1371/journal.pone.0069613